Core Insights - Pfizer has successfully acquired Metsera for $10 billion, outbidding Novo Nordisk, marking a strategic move into the obesity treatment market [4][6][5] Acquisition Details - The acquisition concluded a competitive bidding process, with Pfizer's offer being accepted due to regulatory concerns surrounding Novo Nordisk's bid [5][9] - Pfizer's offer includes $65.60 per share in cash and a contingent value right of up to $20.65 per share based on future milestones [8] Market Context - The obesity drug market is rapidly growing, with an expected global market value of $150 billion by the early 2030s, making it a lucrative area for pharmaceutical companies [11] - Novo Nordisk withdrew from the bidding due to high legal and regulatory risks associated with US antitrust investigations [9][10] Strategic Implications - The acquisition positions Pfizer to compete with market leaders Novo Nordisk and Eli Lilly, which currently dominate the obesity treatment sector [6][11] - Analysts predict that Pfizer needs to generate over $11 billion in sales from Metsera's assets by 2040 to justify the acquisition cost [13] Future Prospects - Metsera's experimental drugs, including MET-097i and MET-233i, could potentially reach combined peak yearly sales of $5 billion if they receive regulatory approval [16] - The deal reflects Pfizer's ambition to diversify its portfolio beyond COVID-19 related products and establish a stronger presence in the obesity treatment market [7][13]